DVDai Hong Phuc Vo

Dai Hong Phuc Vo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dai Hong Phuc Vo has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bone health in prostate cancer: two clinical paradigms and the evolving role of bone-protecting agents

    by Nhu Quang Tran, Jae Young Joung, Kinh Luan Thai, Ho Trong Tan Truong, Hong Phuc Vo Dai

  • Open Access

    Surgical Approach to Redo Open Living Donor Nephrectomy via the Same Flank Incision: A Case Report

    by Hung Ngoc Pham, Can Van Truong, Tuan Kim Nguyen, Phuc Dai Hong Vo, Anh Van Quoc Nguyen, Viet Huu Quoc Phan, Tuan Minh Truong, Thang Vuong Hoang, Hieu Van Le, John Edmondson, et al.

    Living donor nephrectomy is performed with donor safety as the highest priority, and repeat donor nephrectomy through the original incision is rarely reported in transplantation literature. We present the case of a 33‐year‐old male living kidney donor and a 48‐year‐old female recipient who underwent scheduled kidney transplantation. The initial procedure was aborted before vascular ligation because the recipient developed intraoperative anaphylactic shock after anesthesia induction. Three weeks later, transplantation was reattempted using the same donor flank incision. Dense retroperitoneal adhesions were encountered, requiring posterior peritoneal dissection to safely expose the renal hilum and surrounding structures. The donor kidney was successfully harvested and transplanted without postoperative complications. This case demonstrates that repeat open donor nephrectomy via the original incision may be feasible with carefully selected patients with a cautious surgical plan and multidisciplinary perioperative management.

  • Open Access

    Personalizing perioperative therapy in muscle-invasive bladder cancer: balancing oncologic benefit, toxicity, and the risk of overtreatment

    by Geehyun Song, Whi-An Kwon, Eui Hyun Jung, Dai Hong Phuc Vo, Ho Trong Tan Truong, Ho Kyung Seo

    Purpose: Muscle-invasive bladder cancer (MIBC) is an aggressive cancer with a high recurrence risk due to micrometastases. Standard treatment, neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy, is not suitable for all patients, with many being ineligible or experiencing recurrence, alongside significant toxicity concerns.Current Concepts: The introduction of immune checkpoint inhibitors (ICIs) into the perioperative setting —including neoadjuvant ICI use in cisplatin-ineligible patients, adjuvant ICI use in high-risk individuals, and chemoimmunotherapy in either the preoperative or postoperative period—has demonstrated promising clinical outcomes. Additionally, bladder preservation strategies are currently under investigation in select patients who exhibit favorable treatment responses, aiming to maintain quality of life without compromising oncologic outcomes. Nevertheless, challenges such as overtreatment, long-term toxicity, and immune-related adverse events remain significant, underscoring the necessity for precise patient selection.Discussion and Conclusion: To personalize perioperative management of MIBC, it is essential to develop and clinically implement robust predictive biomarkers. Assessment of molecular residual disease using circulating tumor DNA is emerging as a promising method to stratify risk, guide adjuvant treatment decisions, and monitor therapeutic response in real time. Future research should prioritize the validation of these biomarkers, refinement of patient selection criteria for bladder preservation strategies, and evaluation of novel therapeutic agents such as antibody-drug conjugates and fibroblast growth factor receptor inhibitors in the perioperative setting. Ultimately, adopting a precision oncology approach will be critical for balancing oncologic efficacy with toxicity management and achieving patient-centered outcomes.